Clarithromycin use and risk of death in patients with ischemic heart disease

Cardiology

Volumn 116, Issue 2, 2010, Pages 89-97

  Andersen, Søren Skøtt ^a   Hansen, Morten Lock ^a   Norgaard, Mette Lykke ^a   Folke, Fredrik ^a   Fosbøl, Emil Loldrup ^a   Abildstrøm, Steen Z ^b,d   Raunsø, Jakob ^a   Madsen, Mette ^d   Køber, Lars ^c   Gislason, Gunnar H ^a   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chlamydia pneumoniae; Clarithromycin; Ischemic heart disease

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT; TREATMENT OUTCOME; AGED; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HEART MUSCLE ISCHEMIA; HELICOBACTER INFECTIONS; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLARITHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK FACTORS;

EID: 77953016867     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315394     Document Type: Article

References (22)

1. Muhlestein JB, Anderson JL: Infectious serology and atherosclerosis: how burdensome is the risk? Circulation 2003;107:220-222.
2. Gelfand EV, Cannon CP: Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J 2004;147:202-209.
3. Gieffers J, Solbach W, Maass M: In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells. Cardiovasc Drugs Ther 2001; 15:259-262.
4. Borel N, Summersgill JT, Mukhopadhyay S, Miller RD, Ramirez JA, Pospischil A: Evidence for persistent Chlamydia pneumoniae infection of human coronary atheromas. Atherosclerosis 2008;199:154-161.
5. Gupta S, Leatham EW, Carrington D, Men-dall MA, Kaski JC, Camm AJ: Elevated Chla-mydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-407.
6. Andraws R, Berger JS, Brown DL: Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analy-sis of randomized controlled trials. JAMA 2005;293:2641-2647.
7. Song Z, Brassard P, Brophy JM: A meta-anal-ysis of antibiotic use for the secondary prevention of cardiovascular diseases. Can J Cardiol 2008;24:391-395.
8. Jespersen CM, Als-Nielsen B, Damgaard M, et al: Randomised placebo controlled multi-centre trial to assess short term clarithromy-cin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006;332:22-27.
9. Gluud C, Als-Nielsen B, Damgaard M, et al: Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease. Cardiology 2008;111:280-287.
10. Zhu J, Quyyumi AA, Muhlestein JB, et al: Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. Am J Cardiol 2002;89:155-158.
11. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M: The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56: 124-130.
12. Gislason GH, Rasmussen JN, Abildstrom SZ, et al: Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardi-al infarction. Eur Heart J 2006;27:1153-1158.
13. Ables AZ, Simon I, Melton ER: Update on Helicobacter pylori treatment. Am Fam Physician 2007; 75: 351-358.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
15. Rasmussen S, Zwisler AD, Abildstrom SZ, Madsen JK, Madsen M: Hospital variation in mortality after first acute myocardial infarction in Denmark from 1995 to 2002: lower short-term and 1-year mortality in high-volume and specialized hospitals. Med Care 2005;43: 970-978.
16. O'Connor CM, Dunne MW, Pfeffer MA, et al: Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-1466.
17. Grayston JT, Kronmal RA, Jackson LA, et al: Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-1645.
18. Cannon CP, Braunwald E, McCabe CH, et al: Antibiotic treatment of Chlamydia pneu-moniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-1654.
19. Cercek B: Increased risk of mortality following antibiotic treatment in patients with coronary artery disease? Cardiology 2008; 111: 277-279.
20. Gieffers J, Fullgraf H, Jahn J, et al: Chlamyd-ia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-356.
21. Jones HU, Muhlestein JB, Lim TH, et al: Short-term therapy with gatifloxacin or azithromycin prevents the acceleration of atherosclerosis after infection with Chla-mydia pneumoniae in a rabbit model but does not eradicate the organism from plaque. J Am Coll Cardiol 2003;41:289A.
22. Jensen GB, Hilden J, Als-Nielsen B, et al: Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease. J Cardiovasc Pharmacol 2010;55:123-128.